Western blot analysis demonstrated that TA treatment significantly increased the protein levels of p21WAF1/CIP1 and p18INK4C, while it decreased the protein levels of cyclin D1 (G1 phase positive regulator) in prostate cancer cells when compared to control cells (Figure 3B). Here, CDKN2C is linked to prostate carcinoma.